Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb is conducting a study titled The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy. The study aims to assess the safety of deucravacitinib, a drug used to treat psoriasis, during pregnancy by observing outcomes in pregnant participants exposed to the drug. This research is significant as it seeks to ensure the safety of both mothers and infants when using this treatment.
Intervention/Treatment: The study involves the drug deucravacitinib, which is being tested for its safety during pregnancy. Participants are divided into cohorts based on their exposure to deucravacitinib, other systemic treatments for psoriasis, or no exposure to such treatments.
Study Design: This is an observational study with a cohort model. It does not involve any allocation or masking, focusing on observing outcomes in different groups over time. The primary purpose is to gather data on the safety of deucravacitinib during pregnancy.
Study Timeline: The study began on June 4, 2025, which is also the date of the last update. The timeline highlights the ongoing nature of the study, indicating that it is currently recruiting participants.
Market Implications: The results of this study could impact Bristol-Myers Squibb’s stock performance by influencing investor sentiment regarding the safety of deucravacitinib. Positive safety outcomes could enhance the drug’s marketability, while negative results might affect its competitive standing in the psoriasis treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.